Abstract Background In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Background: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been
introduced in the standard therapy of non–small-cell lung cancer (NSCLC), but they benefit …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Introduction The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
gefitinib and erlotinib are gaining an increasing role in the management of advanced non …

Epidermal growth factor receptor (EGFR) has been extensively studied as a target in the
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …

Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …

Tyrosine kinase inhibitors of the epidermal growth factor receptor, gefitinib and erlotinib,
have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) …

Introduction Inhibition of the epidermal growth factor receptor is a promising therapy in the
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …

The epidermal growth factor receptor (EGFR) and its ligands are frequently expressed in
non-small-cell lung cancer (NSCLC). The EGFR tyrosine kinase inhibitors (TKIs) erlotinib …